Adam Szaronos.

WHITE PLAINS, N.Y.—Iantrek, Inc., a medical technology company developing bio-interventional approaches for chronic eye diseases, has appointed Adam Szaronos as its new chief executive officer, effective immediately. According to the announcement, Szaronos succeeds company founder Sean Ianchulev, MD, MPH, who will remain with the company as chairman of the board and chief medical officer. “Iantrek has reached an exciting milestone as we transition from development of our bio-interventional technologies to commercialization and, on behalf of the entire board, we are excited to welcome Adam and bring his leadership and commercial experience to the helm for this next chapter in our growth story,” said Dr. Ianchulev.

“We went through an extensive search process which culminated in Adam’s appointment. I could not be more confident in our ability to execute, given all the talent of our leadership team and our entire organization.”

Szaronos is an ophthalmic industry executive who brings to the position nearly 20 years of industry experience in the pharmaceutical, medical device and medical technology sectors, where he and his teams have worked on more than 50 new technology launches across areas of cataract, refractive and vitreoretinal surgery, diagnostics and digital health.

 
Szaronos most recently served as CEO and president of Trukera Medical. Prior to that, he held numerous sales, marketing and strategic leadership positions at Alcon over a 14-year period, where he was responsible for building new business units and bringing technologies to market, in both the surgical and vision care businesses, the announcement said.

"It’s an honor to be joining the Iantrek team and board at such a pivotal time,” said Szaronos. “As millions of patients fight to prolong the degenerative loss of vision due to glaucoma, the need for interventional treatments to open additional pathways and options for providers has never been greater. Bio-interventional stents and implants, developed from the body’s natural tissue, can uniquely address these needs. Building upon this company’s strong foundation to ensure we now deliver a world-class commercial organization for our physician customers and their patients is my top priority.”

Iantrek’s first two medical devices used in glaucoma surgery, AlloFlo and C-Rex, are in controlled release stage now in the U.S. market, the company said, with plans for a full commercial product launch later this year.